Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Next Science Ltd ( (AU:NXS) ) has shared an update.
Next Science Limited reported a 10% decline in product sales for the second quarter of FY25 compared to the previous year, with sales totaling US$5.2 million. Despite strong growth in direct sales of XPERIENCE and BLASTX, the company faced challenges in the Durable Medical Equipment (DME) channel, impacting overall sales. The company also announced a binding asset purchase agreement with Demetra Holdings S.p.A., subject to shareholder approval, which could influence its market positioning and operations.
The most recent analyst rating on (AU:NXS) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.
More about Next Science Ltd
Next Science Limited is a medical technology company specializing in the commercialization of its proprietary XBIO suite of products aimed at reducing the impact of biofilm-based infections in human health.
Average Trading Volume: 487,092
Technical Sentiment Signal: Sell
Current Market Cap: A$42.43M
For an in-depth examination of NXS stock, go to TipRanks’ Overview page.